Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
72
XERS Quote, Financials, Valuation and Earnings
Last price:
$5.23
Seasonality move
:
6.62%
Day range:
$5.20 - $5.40
52-week range:
$2.10 - $6.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.54x
P/B ratio:
--
Volume:
2.1M
Avg. volume:
2.3M
1-year change:
104.67%
Market cap:
$842.4M
Revenue:
$203.1M
EPS (TTM):
-$0.30
Analysts' Opinion
-
Consensus RatingXeris Biopharma Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.10, Xeris Biopharma Holdings has an estimated upside of 19.77% from its current price of $5.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $5.26.
Fair Value
-
According to the consensus of 5 analysts, Xeris Biopharma Holdings has 19.77% upside to fair value with a price target of $6.10 per share.
XERS vs. S&P 500
-
Over the past 5 trading days, Xeris Biopharma Holdings has underperformed the S&P 500 by -1.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Xeris Biopharma Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xeris Biopharma Holdings has grown year-over-year revenues for 22 quarters straight. In the most recent quarter Xeris Biopharma Holdings reported revenues of $60.1M.
Earnings Growth
-
Xeris Biopharma Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xeris Biopharma Holdings reported earnings per share of -$0.06.
Enterprise value:
1B
EV / Invested capital:
--
Price / LTM sales:
3.54x
EV / EBIT:
--
EV / Revenue:
4.56x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-36.96x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$183M
Return On Assets:
-13.84%
Net Income Margin (TTM):
-20.25%
Return On Equity:
-1019.2%
Return On Invested Capital:
-21.84%
Operating Margin:
-5.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $121.4M | $171.4M | $222.6M | $40.6M | $60.1M | |
| Gross Profit | $99.7M | $142.1M | $183M | $34.7M | $51.4M | |
| Operating Income | -$66.1M | -$45M | -$22.5M | -$14.2M | -$3.1M | |
| EBITDA | -$48M | -$24.7M | -$4.3M | -$8.4M | $1.2M | |
| Diluted EPS | -$0.57 | -$0.46 | -$0.30 | -$0.14 | -$0.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $160.6M | $177.6M | $165.5M | $173.3M | $163.5M | |
| Total Assets | $167.6M | $337.6M | $321.4M | $336.6M | $315.5M | |
| Current Liabilities | $27.4M | $66.5M | $81.4M | $73.1M | $95.1M | |
| Total Liabilities | $123.3M | $241.2M | $291.3M | $345.8M | $350.6M | |
| Total Equity | $44.4M | $96.5M | $30M | -$9.2M | -$35.1M | |
| Total Debt | $87.3M | $138M | $187.6M | $229.7M | $229.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$80.6M | -$41.2M | -$26.7M | -$20.3M | -$10M | |
| Cash From Investing | -$16.2M | $18.3M | $24.5M | -$19.7M | -$13K | |
| Cash From Financing | $48.4M | $34.4M | -$2.2M | $35.2M | -$3.1M | |
| Free Cash Flow | -$81.4M | -$43.4M | -$27.4M | -$20.5M | -$10M | |
XERS
Sector
Market Cap
$842.4M
$34.4M
Price % of 52-Week High
86.66%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
0.06%
-1.01%
1-Year Price Total Return
104.67%
-37.36%
Beta (5-Year)
0.700
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.15
200-day SMA
Buy
Level
$3.97
Bollinger Bands (100)
Buy
Level
4.14 - 5.16
Chaikin Money Flow
Buy
Level
4.8M
20-day SMA
Buy
Level
$4.85
Relative Strength Index (RSI14)
Buy
Level
61.80
ADX Line
Buy
Level
24.81
Williams %R
Neutral
Level
-23.7113
50-day SMA
Buy
Level
$4.77
MACD (12, 26)
Buy
Level
1.44
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.4434)
Sell
CA Score
(Annual)
Level (-3.1445)
Buy
Beneish M-Score
(Annual)
Level (-2.7235)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (5.1426)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Stock Forecast FAQ
In the current month, XERS has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The XERS average analyst price target in the past 3 months is $6.10.
-
Where Will Xeris Biopharma Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xeris Biopharma Holdings share price will rise to $6.10 per share over the next 12 months.
-
What Do Analysts Say About Xeris Biopharma Holdings?
Analysts are divided on their view about Xeris Biopharma Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xeris Biopharma Holdings is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Xeris Biopharma Holdings's Price Target?
The price target for Xeris Biopharma Holdings over the next 1-year time period is forecast to be $6.10 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is XERS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xeris Biopharma Holdings is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XERS?
You can purchase shares of Xeris Biopharma Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xeris Biopharma Holdings shares.
-
What Is The Xeris Biopharma Holdings Share Price Today?
Xeris Biopharma Holdings was last trading at $5.23 per share. This represents the most recent stock quote for Xeris Biopharma Holdings. Yesterday, Xeris Biopharma Holdings closed at $5.26 per share.
-
How To Buy Xeris Biopharma Holdings Stock Online?
In order to purchase Xeris Biopharma Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
